There are two questions behind every drug approval, and the public tends to hear them as one. The first is whether the medicine works. The second is whether you can make it correctly, every single time, in a building the regulator has inspected.
On August 10, ITM disclosed that the FDA had said no to its neuroendocrine tumour therapy on the second question. The first was left untouched.
What the agency actually objected to
ITM received a complete response letter for n.c.a. 177Lu-edotreotide, known in development as ITM-11, for gastroenteropancreatic neuroendocrine tumours. The FDA’s concerns centred on chemistry, manufacturing and controls, plus a third party commercial facility. The clinical package was not the issue. The application had been accepted the previous November with a target decision date already set.
A complete response letter is not a rejection of the science. It is a list of things to fix before the agency will approve. Manufacturing findings are among the more fixable kinds, though rarely quick ones. Remedying a facility observation means changing what a plant does and then proving it.
Why radiopharmaceuticals live and die on logistics
This drug is two things bolted together. Edotreotide is a peptide that seeks out somatostatin receptors. Neuroendocrine tumour cells carry these in unusual abundance. Lutetium-177 is a radioactive isotope that emits beta particles travelling only a couple of millimetres in tissue. The peptide is the address label. The isotope is the payload, delivering radiation to the tumour and very little else.
Lutetium-177 has a half-life of about 6.6 days. Every dose starts decaying the moment it is made. You cannot manufacture a batch in spring and warehouse it. You cannot build a safety stock. You cannot easily reroute a shipment. Each vial is produced, tested, released and flown to a specific patient on a specific day. If the schedule slips, the dose is simply weaker than prescribed. For a tablet, manufacturing is how you make the product. For this, manufacturing is the product.
The “n.c.a.” prefix means no carrier added. It points at the same problem from another direction. Lutetium-177 can be produced with a large fraction of non-radioactive lutetium mixed in. That competing lutetium grabs the same binding sites and dilutes the dose. The no carrier added route avoids this. It is a more demanding process to run consistently, which is exactly the sort of thing a CMC review examines closely.
Why it matters
Radiopharmaceuticals are one of the fastest growing areas in oncology. This is the constraint the field keeps colliding with. The science has moved faster than the supply chains built to carry it. Patients waiting on this drug are waiting on a facility, not a discovery. That is a peculiar and frustrating category of delay.
Cosmael ThinkLab commentary
“The FDA rejected the drug” is the headline that will travel, and it is misleading. Nothing here says the medicine fails to shrink tumours. It says a plant did not satisfy an inspector. Those are different failures with different remedies and very different implications for whether the drug eventually arrives.
It also flags something structural. The third-party facility detail means a specialist contract manufacturer sat in the chain, which is how most of this industry now works, and it means ITM must fix a problem inside a building it does not own. That is a slower conversation than fixing your own line.
Sources: ITM Radiopharma press release (10 August 2026); Fierce Pharma (10 August 2026); OncLive; ITM NDA acceptance and PDUFA announcement (13 November 2025).
Leave a Reply